{
    "xml": "<topic id=\"PHP1775\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/terbutaline-sulfate\" basename=\"terbutaline-sulfate\" title=\"TERBUTALINE SULFATE\">\n<title>TERBUTALINE SULFATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_728\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics-beta2/terbutaline\">Terbutaline</xref>\n</p>\n<data name=\"vtmid\">45311002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_265796086\" title=\"Beta2 agonists (short-acting)\">Beta2 agonists (short-acting)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34629\" title=\"SELECTIVE BETA2 AGONISTS\" namespace=\"/drug-classes/selective-beta2-agonists\">SELECTIVE BETA2 AGONISTS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP46907\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Asthma</p>\n<p outputclass=\"therapeuticIndication\">Other conditions associated with reversible airways obstruction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg 3 times a day for 1&#8211;2 weeks, then increased to up to 5&#8239;mg 3 times a day, use by inhalation preferred over by mouth.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>250&#8211;500&#8239;micrograms up to 4 times a day, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By continuous intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>90&#8211;300&#8239;micrograms/hour for 8-10 hours, to be administered as a solution containing 3&#8211;5&#8239;micrograms/mL, high doses require close monitoring, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;micrograms up to 4 times a day, for persistent symptoms.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of nebulised solution</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8211;10&#8239;mg 2&#8211;4 times a day, additional doses may be necessary in severe acute asthma.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;14 years</p>\n<p>10&#8239;micrograms/kg up to 4 times a day (max. per dose 300&#8239;micrograms), reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 15&#8211;17 years</p>\n<p>250&#8211;500&#8239;micrograms up to 4 times a day, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By continuous intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>Loading dose 2&#8211;4&#8239;micrograms/kg, then 1&#8211;10&#8239;micrograms/kg/hour, dose to be adjusted according to response and heart rate, close monitoring is required for doses above 10&#8239;micrograms/kg/hour, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate, severe, or life-threatening acute asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of nebulised solution</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;4 years</p>\n<p>Initially 5&#8239;mg, then 5&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;11 years</p>\n<p>Initially 5&#8211;10&#8239;mg, then 5&#8211;10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 10&#8239;mg, then 10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 10&#8239;mg, then 10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Exacerbation of reversible airways obstruction (including nocturnal asthma)</p>\n<p outputclass=\"therapeuticIndication\">Prevention of exercise-induced bronchospasm</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;17 years</p>\n<p>500&#8239;micrograms up to 4 times a day, for occasional use only.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;6 years</p>\n<p>75&#8239;micrograms/kg 3 times a day (max. per dose 2.5&#8239;mg).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 7&#8211;14 years</p>\n<p>2.5&#8239;mg 2&#8211;3 times a day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 15&#8211;17 years</p>\n<p>Initially 2.5&#8239;mg 3 times a day, then increased if necessary to 5&#8239;mg 3 times a day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist supervision in hospital)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;micrograms/minute for 20 minutes, then increased in steps of 2.5&#8239;micrograms/minute every 20&#8239;minutes until contractions have ceased (more than 10&#8239;micrograms/minute should <b>seldom</b> be given&#8212;20&#8239;micrograms/minute should <b>not</b> be exceeded), continue for 1 hour, then reduced in steps of 2.5&#8239;micrograms/minute every 20&#8239;minutes to lowest dose that maintains suppression (maximum total duration 48 hours).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"pharmacokinetics\">\n<title>Pharmacokinetics</title>\n<p>At recommended inhaled doses, the duration of action of terbutaline is about 3 to 5 hours.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46860\" outputclass=\"unlicensedUse\" rev=\"1.12\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use in children</p>\n<p>Tablets not licensed for use in children under 7 years.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use or <ph outputclass=\"route\">subcutaneous</ph> use in children</p>\n<p>Injection not licensed for use in children under 2 years.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46951\" outputclass=\"contraindications\" rev=\"1.15\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<sectiondiv outputclass=\"additionalContraindications\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithIndications\">\n<p outputclass=\"title\">When used for uncomplicated premature labour</p>\n<p>\n<ph outputclass=\"routesAndIndications\">with <ph outputclass=\"route\">intravenous</ph> use for uncomplicated premature labour</ph>\n<ph outputclass=\"contraindication\">abruptio placenta</ph> (in adults); <ph outputclass=\"contraindication\">antepartum haemorrhage</ph> (in adults); <ph outputclass=\"contraindication\">cord compression</ph> (in adults); <ph outputclass=\"contraindication\">eclampsia</ph> (in adults); <ph outputclass=\"contraindication\">history of cardiac disease</ph> (in adults); <ph outputclass=\"contraindication\">intra-uterine fetal death</ph> (in adults); <ph outputclass=\"contraindication\">intra-uterine infection</ph> (in adults); <ph outputclass=\"contraindication\">placenta praevia</ph> (in adults); <ph outputclass=\"contraindication\">pulmonary hypertension</ph> (in adults); <ph outputclass=\"contraindication\">severe pre-eclampsia</ph> (in adults); <ph outputclass=\"contraindication\">significant risk factors for myocardial ischaemia</ph> (in adults); <ph outputclass=\"contraindication\">threatened miscarriage</ph> (in adults)</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46958\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Mild to moderate pre-eclampsia (when used for uncomplicated premature labour)</ph> (in adults); <ph outputclass=\"caution\">suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)</ph> (in adults)</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46875\" outputclass=\"sideEffects\" rev=\"1.23\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Nausea</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithIndications\">\n<p outputclass=\"title\">When used for uncomplicated premature labour</p>\n<p>\n<ph outputclass=\"sideEffect\">muscle tension</ph> (in adults); <ph outputclass=\"sideEffect\">pulmonary oedema</ph> (in adults); <ph outputclass=\"sideEffect\">vomiting</ph> (in adults)</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46901\" outputclass=\"pregnancy\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46961\" outputclass=\"breastFeeding\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Inhaled drugs for asthma can be taken as normal during breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46854\" outputclass=\"monitoringRequirements\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient&#8217;s fluid and electrolyte status (avoid over-hydration&#8212;discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46971\" outputclass=\"directionsForAdministration\" rev=\"1.24\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>continuous intravenous infusion</i>, dilute to a concentration of 5&#8239;micrograms/mL with Glucose 5% <i>or</i> Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100&#8239;micrograms/mL.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>For <i>nebulisation</i>, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>bronchodilation</i> by <i>continuous intravenous infusion</i>, dilute 1.5&#8211;2.5&#8239;mg with 500&#8239;mL glucose 5% or sodium chloride 0.9% and give over 8&#8211;10 hours.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>premature labour</i> by <i>continuous intravenous infusion</i>, dilute in glucose 5% and give <i>via</i> controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100&#8239;micrograms/mL; if syringe pump not available dilute to a concentration of 10&#8239;micrograms/mL; close attention to patient's fluid and electrolyte status essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46900\" outputclass=\"patientAndCarerAdvice\" rev=\"1.19\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>\n<i>For inhalation by dry powder</i>, advise patients and carers not to exceed prescribed dose and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a doctor&#8217;s advice should be obtained as soon as possible.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>\n<i>For inhalation by nebuliser</i>, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1775-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/terbutaline-sulfate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76370\" title=\"Tablet\" namespace=\"/drugs/terbutaline-sulfate/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76351\" title=\"Oral solution\" namespace=\"/drugs/terbutaline-sulfate/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76357\" title=\"Solution for injection\" namespace=\"/drugs/terbutaline-sulfate/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76376\" title=\"Inhalation powder\" namespace=\"/drugs/terbutaline-sulfate/inhalation-powder\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76390\" title=\"Nebuliser liquid\" namespace=\"/drugs/terbutaline-sulfate/nebuliser-liquid\">Nebuliser liquid</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP98619\" namespace=\"/guidance/prescribing-in-dental-practice\" title=\"Prescribing in dental practice\" count=\"1\" rel=\"backlink\">Prescribing in dental practice</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78123\" namespace=\"/treatment-summaries/-acute-medical-emergency\" title=\" acute, medical emergency\" count=\"1\" rel=\"backlink\"> acute, medical emergency</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78360\" namespace=\"/treatment-summaries/asthma\" title=\"Asthma\" count=\"2\" rel=\"backlink\">Asthma</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78465\" namespace=\"/treatment-summaries/bronchodilators\" title=\"Bronchodilators\" count=\"4\" rel=\"backlink\">Bronchodilators</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78629\" namespace=\"/treatment-summaries/obstetrics\" title=\"Obstetrics\" count=\"1\" rel=\"backlink\">Obstetrics</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_728\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics-beta2/terbutaline\" title=\"Terbutaline\" count=\"1\" rel=\"link\">Terbutaline</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34629\" namespace=\"/drug-classes/selective-beta2-agonists\" title=\"SELECTIVE BETA2 AGONISTS\" count=\"1\" rel=\"link\">SELECTIVE BETA2 AGONISTS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76370\" namespace=\"/drugs/terbutaline-sulfate/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76351\" namespace=\"/drugs/terbutaline-sulfate/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76357\" namespace=\"/drugs/terbutaline-sulfate/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76376\" namespace=\"/drugs/terbutaline-sulfate/inhalation-powder\" title=\"Inhalation powder\" count=\"1\" rel=\"link\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76390\" namespace=\"/drugs/terbutaline-sulfate/nebuliser-liquid\" title=\"Nebuliser liquid\" count=\"1\" rel=\"link\">Nebuliser liquid</xref>\n</links>\n</topic>",
    "id": "PHP1775",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/terbutaline-sulfate",
    "basename": "terbutaline-sulfate",
    "title": "TERBUTALINE SULFATE",
    "interactants": [
        {
            "id": "bnf_int_728",
            "label": "Terbutaline"
        }
    ],
    "vtmid": "45311002",
    "drugClassification": [
        "Beta2 agonists (short-acting)"
    ],
    "inheritsFromClass": [
        "SELECTIVE BETA2 AGONISTS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Asthma",
                        "html": "Asthma"
                    },
                    {
                        "textContent": "Other conditions associated with reversible airways obstruction",
                        "html": "Other conditions associated with reversible airways obstruction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of nebulised solution"
                    ],
                    "textContent": "By inhalation of nebulised solution",
                    "html": "By inhalation of nebulised solution"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg 3 times a day for 1&#8211;2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth.",
                        "html": "<p>Initially 2.5&#8239;mg 3 times a day for 1&#8211;2 weeks, then increased to up to 5&#8239;mg 3 times a day, use by inhalation preferred over by mouth.</p>"
                    },
                    {
                        "textContent": "250&#8211;500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.",
                        "html": "<p>250&#8211;500&#8239;micrograms up to 4 times a day, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>"
                    },
                    {
                        "textContent": "90&#8211;300 micrograms/hour for 8-10 hours, to be administered as a solution containing 3&#8211;5 micrograms/mL, high doses require close monitoring, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.",
                        "html": "<p>90&#8211;300&#8239;micrograms/hour for 8-10 hours, to be administered as a solution containing 3&#8211;5&#8239;micrograms/mL, high doses require close monitoring, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>"
                    },
                    {
                        "textContent": "500 micrograms up to 4 times a day, for persistent symptoms.",
                        "html": "<p>500&#8239;micrograms up to 4 times a day, for persistent symptoms.</p>"
                    },
                    {
                        "textContent": "5&#8211;10 mg 2&#8211;4 times a day, additional doses may be necessary in severe acute asthma.",
                        "html": "<p>5&#8211;10&#8239;mg 2&#8211;4 times a day, additional doses may be necessary in severe acute asthma.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acute asthma",
                        "html": "Acute asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "continuous intravenous infusion"
                    ],
                    "textContent": "By continuous intravenous infusion",
                    "html": "By continuous intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "10 micrograms/kg up to 4 times a day (max. per dose 300 micrograms), reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.",
                        "html": "<p>10&#8239;micrograms/kg up to 4 times a day (max. per dose 300&#8239;micrograms), reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>",
                        "ageGroup": "2&#8211;14 years"
                    },
                    {
                        "textContent": "250&#8211;500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.",
                        "html": "<p>250&#8211;500&#8239;micrograms up to 4 times a day, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>",
                        "ageGroup": "15&#8211;17 years"
                    },
                    {
                        "textContent": "Loading dose 2&#8211;4 micrograms/kg, then 1&#8211;10 micrograms/kg/hour, dose to be adjusted according to response and heart rate, close monitoring is required for doses above 10 micrograms/kg/hour, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.",
                        "html": "<p>Loading dose 2&#8211;4&#8239;micrograms/kg, then 1&#8211;10&#8239;micrograms/kg/hour, dose to be adjusted according to response and heart rate, close monitoring is required for doses above 10&#8239;micrograms/kg/hour, reserve intravenous beta<sub>2</sub> agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Moderate, severe, or life-threatening acute asthma",
                        "html": "Moderate, severe, or life-threatening acute asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of nebulised solution"
                    ],
                    "textContent": "By inhalation of nebulised solution",
                    "html": "By inhalation of nebulised solution"
                },
                "child": [
                    {
                        "textContent": "Initially 5 mg, then 5 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.",
                        "html": "<p>Initially 5&#8239;mg, then 5&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>",
                        "ageGroup": "1 month&#8211;4 years"
                    },
                    {
                        "textContent": "Initially 5&#8211;10 mg, then 5&#8211;10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.",
                        "html": "<p>Initially 5&#8211;10&#8239;mg, then 5&#8211;10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>",
                        "ageGroup": "5&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 10 mg, then 10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.",
                        "html": "<p>Initially 10&#8239;mg, then 10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 10 mg, then 10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.",
                        "html": "<p>Initially 10&#8239;mg, then 10&#8239;mg every 20&#8211;30&#8239;minutes or when required, give via oxygen-driven nebuliser if available.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Exacerbation of reversible airways obstruction (including nocturnal asthma)",
                        "html": "Exacerbation of reversible airways obstruction (including nocturnal asthma)"
                    },
                    {
                        "textContent": "Prevention of exercise-induced bronchospasm",
                        "html": "Prevention of exercise-induced bronchospasm"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "500 micrograms up to 4 times a day, for occasional use only.",
                        "html": "<p>500&#8239;micrograms up to 4 times a day, for occasional use only.</p>",
                        "ageGroup": "5&#8211;17 years"
                    },
                    {
                        "textContent": "75 micrograms/kg 3 times a day (max. per dose 2.5 mg).",
                        "html": "<p>75&#8239;micrograms/kg 3 times a day (max. per dose 2.5&#8239;mg).</p>",
                        "ageGroup": "1 month&#8211;6 years"
                    },
                    {
                        "textContent": "2.5 mg 2&#8211;3 times a day.",
                        "html": "<p>2.5&#8239;mg 2&#8211;3 times a day.</p>",
                        "ageGroup": "7&#8211;14 years"
                    },
                    {
                        "textContent": "Initially 2.5 mg 3 times a day, then increased if necessary to 5 mg 3 times a day.",
                        "html": "<p>Initially 2.5&#8239;mg 3 times a day, then increased if necessary to 5&#8239;mg 3 times a day.</p>",
                        "ageGroup": "15&#8211;17 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist supervision in hospital)",
                        "html": "Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist supervision in hospital)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 micrograms/minute for 20 minutes, then increased in steps of 2.5 micrograms/minute every 20 minutes until contractions have ceased (more than 10 micrograms/minute should seldom be given&#8212;20 micrograms/minute should not be exceeded), continue for 1 hour, then reduced in steps of 2.5 micrograms/minute every 20 minutes to lowest dose that maintains suppression (maximum total duration 48 hours).",
                        "html": "<p>Initially 5&#8239;micrograms/minute for 20 minutes, then increased in steps of 2.5&#8239;micrograms/minute every 20&#8239;minutes until contractions have ceased (more than 10&#8239;micrograms/minute should <b>seldom</b> be given&#8212;20&#8239;micrograms/minute should <b>not</b> be exceeded), continue for 1 hour, then reduced in steps of 2.5&#8239;micrograms/minute every 20&#8239;minutes to lowest dose that maintains suppression (maximum total duration 48 hours).</p>"
                    }
                ]
            }
        ],
        "pharmacokinetics": [
            {
                "type": "pharmacokinetics",
                "title": "Pharmacokinetics",
                "textContent": "At recommended inhaled doses, the duration of action of terbutaline is about 3 to 5 hours.",
                "html": "<p>At recommended inhaled doses, the duration of action of terbutaline is about 3 to 5 hours.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With oral use in children",
                    "html": "With <ph outputclass=\"route\">oral</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Tablets not licensed for use in children under 7 years.",
                "html": "<p>Tablets not licensed for use in children under 7 years.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With intravenous use or subcutaneous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use or <ph outputclass=\"route\">subcutaneous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous",
                        "subcutaneous"
                    ]
                },
                "textContent": "Injection not licensed for use in children under 2 years.",
                "html": "<p>Injection not licensed for use in children under 2 years.</p>"
            }
        ]
    },
    "contraindications": {
        "cautionsOrContraindicationsWithIndications": [
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "abruptio placenta in adults",
                "html": "abruptio placenta in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "antepartum haemorrhage in adults",
                "html": "antepartum haemorrhage in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "cord compression in adults",
                "html": "cord compression in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "eclampsia in adults",
                "html": "eclampsia in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "history of cardiac disease in adults",
                "html": "history of cardiac disease in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "intra-uterine fetal death in adults",
                "html": "intra-uterine fetal death in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "intra-uterine infection in adults",
                "html": "intra-uterine infection in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "placenta praevia in adults",
                "html": "placenta praevia in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "pulmonary hypertension in adults",
                "html": "pulmonary hypertension in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "severe pre-eclampsia in adults",
                "html": "severe pre-eclampsia in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "significant risk factors for myocardial ischaemia in adults",
                "html": "significant risk factors for myocardial ischaemia in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "threatened miscarriage in adults",
                "html": "threatened miscarriage in adults",
                "specificity": {
                    "routes": [
                        "intravenous"
                    ],
                    "textContent": "When used for uncomplicated premature labour",
                    "html": "When used for uncomplicated premature labour",
                    "indications": [
                        "uncomplicated premature labour"
                    ],
                    "patientType": "adults"
                }
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Mild to moderate pre-eclampsia (when used for uncomplicated premature labour) in adults",
                "html": "Mild to moderate pre-eclampsia (when used for uncomplicated premature labour) in adults",
                "specificity": {
                    "patientType": "adults"
                }
            },
            {
                "type": "cautions",
                "textContent": "suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour) in adults",
                "html": "suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour) in adults",
                "specificity": {
                    "patientType": "adults"
                }
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Nausea",
                        "html": "Nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "sideEffectsWithIndications",
                        "textContent": "muscle tension in adults",
                        "html": "muscle tension in adults",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used for uncomplicated premature labour",
                            "html": "When used for uncomplicated premature labour",
                            "indications": [
                                "uncomplicated premature labour"
                            ],
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "sideEffectsWithIndications",
                        "textContent": "pulmonary oedema in adults",
                        "html": "pulmonary oedema in adults",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used for uncomplicated premature labour",
                            "html": "When used for uncomplicated premature labour",
                            "indications": [
                                "uncomplicated premature labour"
                            ],
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "sideEffectsWithIndications",
                        "textContent": "vomiting in adults",
                        "html": "vomiting in adults",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used for uncomplicated premature labour",
                            "html": "When used for uncomplicated premature labour",
                            "indications": [
                                "uncomplicated premature labour"
                            ],
                            "patientType": "adults"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Inhaled drugs for asthma can be taken as normal during pregnancy.",
                "html": "<p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Inhaled drugs for asthma can be taken as normal during breast-feeding.",
                "html": "<p>Inhaled drugs for asthma can be taken as normal during breast-feeding.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient&#8217;s fluid and electrolyte status (avoid over-hydration&#8212;discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).",
                "html": "<p>In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient&#8217;s fluid and electrolyte status (avoid over-hydration&#8212;discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For continuous intravenous infusion, dilute to a concentration of 5 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100 micrograms/mL.",
                "html": "<p>For <i>continuous intravenous infusion</i>, dilute to a concentration of 5&#8239;micrograms/mL with Glucose 5% <i>or</i> Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100&#8239;micrograms/mL.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "For nebulisation, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.",
                "html": "<p>For <i>nebulisation</i>, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For bronchodilation by continuous intravenous infusion, dilute 1.5&#8211;2.5 mg with 500 mL glucose 5% or sodium chloride 0.9% and give over 8&#8211;10 hours.",
                "html": "<p>For <i>bronchodilation</i> by <i>continuous intravenous infusion</i>, dilute 1.5&#8211;2.5&#8239;mg with 500&#8239;mL glucose 5% or sodium chloride 0.9% and give over 8&#8211;10 hours.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For premature labour by continuous intravenous infusion, dilute in glucose 5% and give via controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100 micrograms/mL; if syringe pump not available dilute to a concentration of 10 micrograms/mL; close attention to patient's fluid and electrolyte status essential.",
                "html": "<p>For <i>premature labour</i> by <i>continuous intravenous infusion</i>, dilute in glucose 5% and give <i>via</i> controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100&#8239;micrograms/mL; if syringe pump not available dilute to a concentration of 10&#8239;micrograms/mL; close attention to patient's fluid and electrolyte status essential.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "For inhalation by dry powder, advise patients and carers not to exceed prescribed dose and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a doctor&#8217;s advice should be obtained as soon as possible.",
                "html": "<p>\n<i>For inhalation by dry powder</i>, advise patients and carers not to exceed prescribed dose and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a doctor&#8217;s advice should be obtained as soon as possible.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "For inhalation by nebuliser, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.",
                "html": "<p>\n<i>For inhalation by nebuliser</i>, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76370",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76351",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76357",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76376",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76390",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP98619",
                "label": "Prescribing in dental practice",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78123",
                "label": "acute, medical emergency",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78360",
                "label": "Asthma",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78465",
                "label": "Bronchodilators",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78629",
                "label": "Obstetrics",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_728",
                "label": "Terbutaline",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34629",
                "label": "SELECTIVE BETA2 AGONISTS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76370",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76351",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76357",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76376",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76390",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            }
        ]
    }
}